https://www.selleckchem.com/products/fiin-2.html
Platform robustness was proven with both technical and biological replicates and subsequently the platform was used to screen for the most favourable conditions for production of a pneumococcal serotype 4 vaccine candidate. This work establishes an effective automated platform that enabled the identification of the most suitable E. coli strain and genetic constructs to be used in ongoing early phase research and be further brought into preclinical trials. Patients with locally advanced sigmoid colon cancer (LASCC) have limited treatment
Like
Comment
Share
